NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two cycles of induction treatment, defined as the proportion of patients who have achieved sCR, according to International Myeloma Working Group (IMWG) criteria, by the end of two cycles of induction treatment.

Sponsor

Cancer Trials Ireland

Collaborators

Sanofi

Dana-Farber Cancer Institute

Locations

Denmark

Ireland

---

ClinicalTrials.gov Identifier: NCT05123131

Official Title: Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

First Posted : November 17, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: Isatuximab

Drug: Bortezomib

Drug: Lenalidomide

Drug: Dexamethasone (IV)

---

Locations

Europe

Denmark

Ireland